MX2021010115A - Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda. - Google Patents

Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda.

Info

Publication number
MX2021010115A
MX2021010115A MX2021010115A MX2021010115A MX2021010115A MX 2021010115 A MX2021010115 A MX 2021010115A MX 2021010115 A MX2021010115 A MX 2021010115A MX 2021010115 A MX2021010115 A MX 2021010115A MX 2021010115 A MX2021010115 A MX 2021010115A
Authority
MX
Mexico
Prior art keywords
myeloid leukemia
acute myeloid
pharmaceutical composition
hypomethylating agent
treating acute
Prior art date
Application number
MX2021010115A
Other languages
English (en)
Inventor
In Hwan Bae
Young Gil Ahn
Ji Sook Kim
Jae Yul Choi
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Priority claimed from KR1020200021502A external-priority patent/KR20200102949A/ko
Publication of MX2021010115A publication Critical patent/MX2021010115A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona una composición farmacéutica para tratar la leucemia mieloide aguda (LMA), comprendiendo la composición farmacéutica un inhibidor de tirosina cinasa de tipo Fms (tirosina cinasa 3 de tipo Fms: FLT3) o una sal o solvato farmacéuticamente aceptable del mismo y un agente hipometilante (AHM) o una sal o solvato farmacéuticamente aceptable del mismo en una combinación terapéuticamente eficaz, y un método de tratamiento de la LMA usando la misma.
MX2021010115A 2019-02-22 2020-02-21 Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda. MX2021010115A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20190021228 2019-02-22
PCT/KR2020/002536 WO2020171646A1 (ko) 2019-02-22 2020-02-21 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물
KR1020200021502A KR20200102949A (ko) 2019-02-22 2020-02-21 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물

Publications (1)

Publication Number Publication Date
MX2021010115A true MX2021010115A (es) 2021-09-21

Family

ID=72144358

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010115A MX2021010115A (es) 2019-02-22 2020-02-21 Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda.

Country Status (7)

Country Link
US (1) US20220110913A1 (es)
JP (1) JP2022521380A (es)
BR (1) BR112021016522A2 (es)
CL (1) CL2021002217A1 (es)
MX (1) MX2021010115A (es)
PE (1) PE20212153A1 (es)
WO (1) WO2020171646A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
WO2023225005A1 (en) 2022-05-17 2023-11-23 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2670498A1 (en) 2006-11-28 2008-06-05 Novartis Ag Combination of iap inhibitors and flt3 inhibitors
US20110183975A1 (en) * 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
KR20180124055A (ko) 2016-03-29 2018-11-20 아스테라스 세이야쿠 가부시키가이샤 급성 골수성 백혈병의 치료를 위한 병용 요법
KR102175710B1 (ko) 2017-01-23 2020-11-06 주식회사 엘지화학 폴리아릴렌 설파이드 수지 조성물
AR110778A1 (es) 2017-01-26 2019-05-02 Hanmi Pharm Ind Co Ltd Compuestos de pirimidina y su uso farmacéutico
KR101954370B1 (ko) * 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물

Also Published As

Publication number Publication date
WO2020171646A1 (ko) 2020-08-27
CL2021002217A1 (es) 2022-04-29
BR112021016522A2 (pt) 2021-10-26
US20220110913A1 (en) 2022-04-14
PE20212153A1 (es) 2021-11-09
JP2022521380A (ja) 2022-04-07

Similar Documents

Publication Publication Date Title
MX2021010115A (es) Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda.
MX2021015724A (es) Composición farmacéutica para el tratamiento de la leucemia mieloide aguda, que contiene inhibidores de flt3 y agentes quimioterapéuticos.
MX2022006865A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
MX2023010411A (es) Inhibidores de erbb/btk.
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
MX2023008954A (es) Inhibidores de los receptores erbb.
MX2021009444A (es) Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7.
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2022002196A (es) Composición de liberación retardada de niclosamida y uso antiviral de la misma.
WO2018102687A3 (en) Combination therapy for treating cancer
MX2017012123A (es) Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer.
MX2021008010A (es) Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld).
MX2020010618A (es) Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a.
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
PH12021550965A1 (en) Combination therapy for treatment of hematological diseases
MX2021007247A (es) Derivados de rapamicina.
MX2021007948A (es) Inhibidores de proteina de activacion de fibroblastos.
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
MX2020011453A (es) Combinaciones para tratar el cancer.
MX2022004027A (es) Farmaco farmaceutico que contiene derivado de heterocicliden acetamida.
EA202191984A1 (ru) Фармацевтическая композиция, содержащая ингибитор flt3 и гипометилирующий агент, для лечения острого миелолейкоза
ZA202206308B (en) Ezetimibe and curcumin for use in cancer treatment
ZA202106519B (en) Caspase inhibitors and methods of use thereof
PH12020551772A1 (en) Oxo-substituted compound
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.